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Abstract
Purpose. The present prospective randomized adjuvant trial was carried out to compare the toxicity,feasibility and efficacy
of augmented chemotherapy added to hyperfractionated accelerated radiotherapy after wide or marginal resection of grade
2 and grade 3 soft tissue sarcoma (STS).
Patients and methods. Fifty-nine patients underwent primary surgery by wide or marginal excision and were subsequently
randomized to receive radiotherapy alone or under the addition of six courses of ifosfamide (1500 mg/m
2, days 1± 4), dacar-
bazine (DTIC) (200 mg/m
2, days 1± 4) and doxorubicin (25 mg/m
2, days 1± 2) administered in 14-day-intervals supported
by granulocyte-colony stimulating factor (303 10
6 IU/day, s.c.) on days 5± 13. According to the randomization protocol, 28
patients received radiotherapy only, whereas 31 patients were treated with additional chemotherapy.
Results. The relative ifosfamide± doxorubicin± DTIC (IFADIC) dose intensity achieved was 93%.After a mean observation
period of 41±19.7 months (range, 8.1± 84 months), 16 patients (57%) in the control group versus 24 patients (77%) in the
chemotherapy group were free of disease (p>0.05).Within the control group, tumor relapses occurred in 12 patients (43%;
six patients with distant metastases, two with local relapse, four with both) versus seven patients (23%; ® ve patients with
distant metastases, one with local recurrence, one with both) from the chemotherapy group. Relapse-free survival (RFS)
(p=0.1), time to local failure (TLF) (p=0.09),time to distant failure (TDF) (p=0.17) as well as overall survival (OS) (p=0.4)
did not differ signi® cantly between the two treatment groups. Treatment-related toxicity was generally mild in both
treatment arms.
Conclusion. We concludethat the safety pro® le of intensi® ed IFADIC added to radiotherapy was manageable and tolerable
in the current setting. Inclusion of intensi® ed IFADIC was not translated into a signi® cant bene® t concerning OS, RFS,
TLF andTDF as compared with radiotherapy only, although a potential bene® t of chemotherapy for grade 3 STS patients
needs to be validated in prospective randomized trials including larger patient numbers.
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Introduction
Patients with high-grade soft tissue sarcomas (STS)
treated by local tumor removal remain free of relapse
in approximately 40± 60%, whereas overall survival
rates rangebetween 50 and 70%.
1± 3As surgicalresec-
tion represents the mainstay of treatment in adult
extremity STS,the outcome dependson high-quality
preoperative tumor imaging followed by an optimal
surgical approach that should keep an equilibrium
between complete removal of malignancy and a
minimum of functional impairment.The use of adju-
vant radiotherapy (RT) after wide or compartmental
surgery of STS varies between centers, and in some
geographic areas is restricted to patients with
histopathologic intermediate- or high-grade STS.
4,5
Other centersapply adjuvant RT regardlessof surgical
margins and malignancy grade.
6,7 However, an area
including the complete extension of the initial tumor
with its risk zone and the entire scar need to be
treated. In an attempt to reduce the rate of local
relapses, hyperfractionated RT has emerged as an
attractive possibility in the treatment of sarcomas.
8
However,despite re® nements in local therapy, distant
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high-grade STS.
9 Consequently, prospective rand-
omized studies on the efficacy of adjuvant
chemotherapy (CT) have been carried out, and
resulted in the demonstration of a favorable effect
upon both relapse-free (RFS) and overall survival
(OS) in three studies,
10± 13 whereas three further
studies showeda signi® cant bene® t for RFS only.
14± 16
Finally, a recently published meta-analysis showed
an absolute improvement for patients with STS
resulting from the administration of adjuvant CT
concerning overall (absolute bene® t 10%), local
(absolute bene® t 6%) and distant recurrence-free
survival (absolute bene® t 10%) at 10 years.
17
Cytotoxic agents most frequently used in polyche-
motherapy for STS include doxorubicin,ifosfamide,
cyclophosphamide and DTIC. The Southwestern
Oncology Group has reported on a 50% response
rate of recurrent/metastatic STS following the
administration of a combination of doxorubicin,
DTIC, cyclophosphamide and vincristine
(CYVADIC),
18 whereas another chemotherapeutic
combination used for this indication has been put
together to include agents with the highest single-
agent activity in adult STS,
19 including ifosfamide,
doxorubicin and DTIC (IFADIC).
20,21
Ever since the concept of dose intensity addition-
ally de® ningefficacy of chemotherapy
22has emerged,
several trials testing this hypothesis have been
published.
23 However, despite the lack of clear-cut
data on the efficacy of adjuvant CT in STS, only few
trials have attempted to improve results of this treat-
ment modality by augmenting the dose of cytotoxic
agents.
13,15,24,25 As an augmentation of dose can be
achieved by either an increase in the amount of
drug(s) administered or by an abbreviation of time
intervals between treatment courses,
26 we used the
latter approach and administered the IFADIC
regimen in 14-day intervals with granulocyte-colony
stimulating factor (G-CSF) support.
We now report the results of a prospective adju-
vant feasibility trial performed in patients with STS
after wide or marginal resection of malignancy and
subsequent hyperfractionated accelerated RT rand-
omizing between no further treatment and additional
augmented CT with IFADIC.After a mean observa-
tion period of 41±19.7 months (range, 8.1± 84
months), no signi® cant differences in the duration of
RFS, time to local failure (TLF) as well as time to
distant failure (TDF) or OS (p>0.05) between the
two treatment groupshave emerged.Thesafety profile
of intensi® ed CT with IFADIC addedto radiotherapy
was manageable and tolerable.
Patients and methods
Patients
The study was initiated in January 1992 and
conducted according to the declaration of Helsinki
after having been approved by the local ethical
committee. After a mean observation period of
41±19.7 months (range, 8.1± 84 months), 59 STS
patients (27 females,32 males) with a mean age of 52
years (range, 20± 77 years) were included.
Characteristics of patients are presented in Table 1.
Primary endpoints were treatment-related toxicities
and dose intensity. RFS, TLF, TDF and OS
constituted secondary endpoints.
Table 1. Patients’ characteristics
RT and CT (n=31) RT (n=28)
Characteristics
Mean age (years)±SD (range) 49±14.5 (20± 71) 54±15.4 (21± 77)
Female/male 13/18 14/14
Mean tumor size (cm)±SD (range) 9.4±4.9 (2.5± 20) 8.8±4.2 (1± 18)
Histology
Liposarcoma 6 9
MFH 6 5
Synovial sarcoma 4 3
Leiomyosarcoma 6 0
Malignant schwannoma 1 0
Fibrosarcoma 2 2
Rhabdomyosarcoma 0 2
Other types of STS 6 7
Tumor location
Upper extremity 9 2
Lower extremity 16 20
Trunk 5 6
Retroperitoneum 1 0
Tumor grading
G2 6 12
G3 25 16
CT, Chemotherapy; MFH, malignant ® brous histiocytoma; RT, radiotherapy; STS, soft
tissue sarcoma.
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Inclusioncriteria consistedof histopathologically veri-
® ed grade 2 (tumor size >5 cm) or grade 3 (any
tumor size) STS, performance status World Health
Organization (WHO) 0± 1 (=Karnofsky ‡ 60), an age
of 18± 80 years,serum total bilirubin and/or transami-
nase levels £ 1.25 times the upper limits of normal,
serum creatinine £ 2 mg/100 ml, and an adequate
hematologic function (as de® ned by white blood cells
‡ 3.03 10
9/l, platelets ‡ 1003 10
9/l). Histologic entities
included ® brosarcoma, malignant ® brous histiocy-
toma, liposarcoma, leiomyosarcoma, rhabdomyosar-
coma, synovial sarcoma, malignant schwannoma,
epitheloid sarcoma, clear cell sarcoma and mixed
tumors of soft tissue origin.
Exclusion criteria
Exclusion criteria consisted of previous chemo- or
radiotherapeutic treatment of the current disease,
intralesional resection of the primary tumor (see
`Treatmentprotocol’ section),local relapseof previous
STS, the presence of distant metastases at time of
diagnosis, surgical resection being carried out >4
weeks before randomization,secondmalignancywith
the exception of in situ cervical cancer or adequately
excised basal cell or squamous cell carcinoma of the
skin, left ventricular ejection fraction £ 50%, history
of atrial or ventricular arrhythmias,histologic entities
includingneuroblastoma,primitive neuroectodermal
tumor (PNET), Ewing sarcoma, extraskeletal oste-
osarcoma and embryonal rhabdomyosarcoma, active
infection or any other serious underlying medical
condition that would impair the ability of the patient
to receivetreatment accordingto the protocol,altered
mental status that would prohibit the understanding
and giving of informedconsent,pregnancyand breast
feeding.
Randomization and strati® cation
Patients after wide or marginal surgical resection of
histopathologically veri® ed STS were randomized to
receive either RT only or a combination of RT and
CT. Strati® cation was carried out according to, ® rst,
location of the tumor (extremities versus trunk),
second,age (£ 45 years versus46± 80 years) and,third,
the randomizing center.
Treatment protocol
Surgery and pathohistologic work-up. Surgery. To
achieve local tumor control, adequate surgery with
tumor-free resection margins was required,
representing the most important prerequisite.Thus,
only patients after marginal or wide resection of STS
were included in this study. Preoperative planning
was performed after staging with computerized
tomography and/or magnetic resonance imaging of
the tumorregionand,in case of involvementof vessels
or nerves, angiography. Primary resection was
performed with respect to adequate resection
margins. To achieve limb salvage, endoprostheses
were used to replace the resected bone if necessary.
Moreover,reconstruction of vessels and nerves,and
plastic surgery using free ¯ aps or rotational ¯ aps
and skin grafts to cover the defect were performed.
Resection margins were evaluated according to
Enneking:
27 wide resection was de® ned as en bloc
excision performed through healthy tissue beyond
the reactive zone. Resection was de® ned as marginal
if the resection was carried out extracapsularly but
through the reaction zone surrounding the tumor.
Patients with intralesional (intratumoral) resec-
tions were excluded.
28
Histopathologic analysis. Central histopathology
review was a prerequisite for inclusion of patients
and was performed by Prof. M. Salzer-Kuntschik,
Dr G. Amann and Dr S. Lang from the Depart-
ment of Clinical Pathology at the University
Hospital of Vienna. Acting as referral pathologists,
histopathologic diagnosis was required to be made
by at least two pathologists independently and with
identical outcome. Both tumor classi® cation and
grading was performed according to Enzinger and
Weiss, and Fletcher.
29,30 Grading was based on the
modi® ed scheme from Coindre using the following
three parameters: (1) degree of tumor differentia-
tion, with scores 1± 3 including clearly recognizable
entities such as alveolar soft part sarcoma in the
group with score 2; (2) tumor necrosis, with scores
0± 2; and (3) mitotic count with scores 1± 3
corresponding to <10, <20 and ‡ 20 mitosis per 10
high-power ® elds.
Grade 1 tumors were thereby de® ned by a total
score of £ 3. Grade 2 included tumors with a total
score of 4 and 5. A total score of ‡ 6 de® ned grade 3
malignancy.
Adjuvant augmented chemotherapy. Ifosfamide
(1500 mg/m
2, days 1± 4), DTIC (200 mg/m
2, days
1± 4) and doxorubicin (25 mg/m
2, days 1 and 2;
IFADIC) were administered intravenously in a
14-day-cycle. G-CSF (Neupogen, Roche) (303 10
6
IU/day) was injected subcutaneously on days 5± 13.
The ® rst course of chemotherapy started within 28
days following STS resection,and a total of six cycles
of chemotherapy was given. In the case of randomi-
zation into the chemotherapy arm, radiotherapy was
administered during cycles 3 and 4. Cycles 3 and 4
contained no doxorubicin due to concomitant
radiotherapy.
Supportive therapy. Standard anti-emetic medica-
tion consistedof 5-HT3-antagonists and metoclopra-
mide.Hydration was carried out as indicated.Mesna
uroprotectionat 300 mg/m
2i.v.was given 30 minutes
beforeand 4 and 8 hoursafter ifosfamide.Substitution
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2 was allowed for the 4-
and 8-hour i.v. doses.
Adjuvant hyperfractionated accelerated radiotherapy.
Radiotherapy consistedof 51 Gy within 3 weeks to
be administered in single fractions of 1.7 Gy twice
daily with an interfraction interval of at least 6 hours.
The target volume encompassedthe compartment of
the primary tumor location and included the entire
scar. Dose was calculated at the ICRU point. If the
spinal cord, small intestine, or lung was in the ® eld,
conventional fractionation to a total dose of 50± 60
Gy was to be administered.
Evaluation of patients. Before randomization was
carried out, patients were staged according to the
TNM classi® cation for STS.Inaddition,the following
procedures were performed. Obligatory: physical
examination, laboratory tests for hematologic assess-
ment and blood chemistry, chest X-ray, abdominal
ultrasound, total body bone scintigraphy, computer-
ized tomography or magnetic resonance imaging of
the previous tumor bed and, ® nally, histopathologic
examination including identi® cation of type of
malignancy and histopathologic grading.
Hematologic as well as non-hematologic toxicities
were assessed according toWHO criteria on day 1 of
each chemotherapy cycle. Local toxicity was assessed
at the end of radiotherapy. Chronic local toxicity was
assessed during follow-up evaluations. After
completingtreatment,the patients’ status was assessed
in intervals of 4 months and included physical
examination,laboratory tests,chest X-ray, abdominal
ultrasound and computerized tomography or
magnetic resonance imaging of the previous tumor
bed.
Dose modi® cations. Cytotoxic drug administration
was delayed by 1 week in case of no full hematologic
recovery (white blood cells ‡ 3.03 10
9/l, platelets
‡ 1003 10
9/l) from the prior chemotherapy cycle.
Dose intensity.
31 Treatment duration was calculated
as time between the ® rst and ® nal cytotoxic drug
administration plus 14 days, representing the
theoretical duration of one treatment cycle.The total
administered dose represented the sum of all
administered doses per square meter. Relative dose
intensity was calculated by dividing the total
administered dose in milligrams by total duration in
days, and subsequently expressed as the percentage
of initially planned theoretical dose intensity.
Statistical analysis
Relapse-free and overall survival were secondary end
points for the study.Data are givenas mean±standard
deviation. Statistical calculations were carried out by
log-rank test (overall survival, relapse-free survival,
time to local failure, time to distant failure) or
chi-square test (response rates, toxicity), both
performed with the BMDP-PC program package
using a level of signi® cance of 0.05 (two-sided).Data
were analyzed on an intent-to-treat basis. Fifty
patients/treatment arm were aimed to be included in
this study over an expected time period of 48 months.
However, accrual was lower than expected and
subsequently closed after the inclusion of a total of
59 patients.For relapse-freesurvival analysis,patients
were consideredto have failed treatment at relapse or
death and were censored at the date of last contact if
alive without relapse. For analyses of time to distant
or local failure,patients were consideredto have failed
treatment at occurrence of distant metastases or at
local recurrence, and were censored at the date of
last contact or death without distant or local recur-
rence.
Results
Treatment-associated toxicity
Systemic toxicity of adjuvant augmented chemotherapy+
hyperfractionated accelerated radiotherapy. The mean
number of administered courses of chemotherapy
was 5.7±1 (range,2± 6).Treatment-related toxicity in
patients receiving chemotherapy was generally mild.
A detailed description of toxicities is presented in
Table 2.No systemic toxicity was observed in patients
receiving radiotherapy only.
In detail, treatment-associated toxicity in patients
from the chemotherapy group included alopecia of
WHO grade 3 in all cases,leukopeniaofWHO grades
1 and 2 in 19 patients (61%), grade 3 in four patients
(13%) and grade 4 in four patients (13%), thrombo-
cytopenia grades 1 and 2 in seven patients (23%),
grade 3 in one patient (3%) and grade 4 in one
Table 2. Treatment-associated systemic toxicity in 31 patients receiving adjuvant
radiotherapy+adjuvant chemotherapy
WHO grade
I II III IV
Leukopenia 11 (35%) 8 (26%) 4 (13%) 4 (13%)
Thrombocytopenia 5 (16%) 2 (6%) 1 (3%) 1 (3%)
Alopecia 0 0 31 (100%) 0
WHO,World Health Organization.
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stomatitis WHO grade 3 in 1 patient (3%). Due to
standard anti-emetic medication with 5-HT3-
antagonists combined with metoclopramide, no
episodes of emesis grades III or IV occurred.
Furthermore,none of the patients developed neutro-
penic sepsis.In two patients (6%), chemotherapy was
discontinued after two cycles due to impairment of
wound healing.
Local toxicity of radiotherapy. Generally, acute local
toxicity from radiotherapy was mild. Most patients
showed an erythema and dry desquamation; two
(control group) versus three (chemotherapy group)
patients had a moist desquamation. Local toxicities
were individual in nature: no excessive ® brosis with
considerablefunctional impairment was found.One
infected endoprosthesis had to be removed in each
group, respectively. One patient suffered from a
fracture of his irradiated thigh, which occurred
simultaneously with marked ® brosis and lymph-
edema 3 years after treatment (chemotherapy
group). One last patient underwent limb amputa-
tion 7 months after treatment due to recurring
® stulae and bone necrosis in the absence of tumor
recurrence (chemotherapy group).
Dose intensity
Patients randomized to the chemotherapy arm
received a mean number of 5.7±1 (range, 2± 6)
chemotherapy cycles, all of which were given in the
assigned dose. CT was discontinued in two patients
after two cycles due to wound healing impairment.
Thus, a total of 178 cycles were administered.Treat-
ment was delayed in 21 cycles (11.8% of cycles,
19.4% of patients) due to hematologic toxicity. No
cycle was delayed for >2 weeks and no dose reduc-
tions were necessary. Mean duration of treatment
was 86.5±20.7 days (range, 28133 days). Mean
administereddoses of ifosfamide,DTIC and doxoru-
bicin were 34452±5994 mg/m
2 (range, 12 000± 36
000 mg/m
2), 4594±799 mg/m
2 (range, 1600±
4800 mg/m
2) and 194±25 mg/m
2 (range,
100± 200 mg/m
2), respectively.Relative dose intensity
was 93%.
Response to treatment
RFS,TLF,TDF and OS. After a mean follow-up of
41±19.7 months (range,8.1± 84 months),16 patients
(57%) from the control group versus 24 patients
(77%) from the chemotherapy grouphad no evidence
of tumor recurrence (Table 3). In contrast, recurrent
disease developed in 12 patients (43%) treated with
radiotherapy alone versus seven (23%) patients who
received additional chemotherapy (p>0.05) (Table
3). The median dose of radiotherapy was 51 Gy
(mean, 50 Gy) and median duration of radiotherapy
was 21 days (mean, 27 days) with no difference
between randomization groups (p>0.1).
Sites of relapses. The sites of STS relapses were as
follows (Table 3). In the control group, six patients
presented with lung metastases, two patients with
local recurrence and four patients with both. In the
chemotherapy group, ® ve patients developed lung
metastases, one patient local recurrence and one
patient local relapse and lung metastases. Local
failures occurred within the ® rst 3 years following
surgical removal of the primary tumor, whereas
distant failures occurred up to 3.6 years after
surgery.Overall, four patients died:one patient from
each treatment group due to tumor progression,
and two additional patients from the control group
due to myocardial infarction that occurred 1 and
13 months after wide surgical resection of malignant
® brous histiocytoma of the left leg, respectively. As
shown in a Kaplan± Meier analysis, RFS (p=0.1)
(Fig. 1b), TLF (p=0.09) (Fig. 1c), TDF (p=0.17)
(Fig. 1d) as well as OS (p=0.4) (Fig. 1a) did not
differ signi® cantly between the two treatment
groups. However, patients randomized to receive
chemotherapy tended to develop less local failures,
as compared with patients receiving radiotherapy
only (p=0.09). In a subgroup analysis, tumor size
and histopathologic grading were analyzed and put
into relation with response to treatment. Whereas
tumor size was well balanced and without impact
upon response to treatment (Table 4), histologic
grading emerged to be of signi® cant importance
upon response to treatment concerning variables of
disease outcome.
Table 3. Responses to treatment
Reponse rates RT and CT (n=31) RT (n=28)
No evidence of tumor recurrence (%) 24 (77%) 16 (57%)
Overall relapses (%) 7 (23%) 12 (43%)
Local failures (%) 2 (6%)
1 6 (21%)
2
Distant failures (%) 6 (19%)
1 10 (36%)
2
1Including one patient with local relapse and lung metastases.
2Including four patients with local relapse and lung metastases.
CT, Chemotherapy; RT, radiotherapy.
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Subgroup analysis of patients with grade 3 STS
versus patients with grade 2 STS was carried out: 16
patients with grade 3 STS received radiotherapy only
versus 25 patients who underwent additional
chemotherapy.Seven patients (44%) from the control
group versus 19 patients (76%) from the
chemotherapy grouphad no evidence of tumor recur-
rence (Table 4). Tumor relapse occurred in nine
patients (56%) treated with radiotherapy alone versus
six (24%) patients who received additional
chemotherapy (p<0.05, two-sided) (Table 4).
Sites of tumor recurrences were as follows (Table
4). In the control group, eight patients (50%)
presented with lung metastases, including four who
had additional local relapse. One further patient had
local relapse alone. In contrast, in the chemotherapy
group, ® ve patients (20%; p<0.05, two-sided)
developed lung metastases,includingone patient with
additionallocal relapse.Onefurther patient presented
with local recurrence alone. An actuarial analysis of
patients with grade 3 STS is shown in Figure 2: a
signi® cant advantage for both RFS (p=0.03,
two-sided) (Fig. 2b) and TDF (p=0.03, two-sided)
(Fig. 2d) was observed in patients receiving
chemotherapy,as compared with patients treated with
radiotherapy only. In contrast, Kaplan± Meier plots
forTLF (p=0.06) (Fig. 2c) and OS (p=0.4) (Fig. 2a)
did not differ signi® cantly.
Response to treatment,RFS,TLF,TDF and OS in patients
with grade 2 STS. Considering grade 2 STS, 12
patients with grade 2 STS received radiotherapy only
versus six patients who underwent additional
chemotherapy. Nine patients (75%) from the control
group versus ® ve patients (83%) from the
chemotherapy grouphad no evidenceof tumorrecur-
rence.Tumor relapseoccurredin three patients (25%)
treated with radiotherapy alone (one local failure,
two distant failures) versus one (17%) patient who
received additional chemotherapy and subsequently
developed lung metastases (p>0.05). No signi® cant
difference regarding RFS, TLF, TDF or OS was
observed (p>0.05), respectively (plots not shown).
Discussion
Inthis study,59 patients with histopathologicallyveri-
® ed STS underwent primary surgery by wide or
marginal resection and were subsequently rand-
omized to receive either adjuvant RT alone or, in a
combined modality approach, under the inclusion of
six adjuvant courses of the IFADIC chemotherapy
regimen augmented in time. After a mean observa-
tion period of 41 months and an analysis of all
included patients, the present trial did not show any
signi® cant difference favoring either approach
concerning RFS, TLF, TDF or OS. Application of
the intensi® ed IFADIC regimen was associated with
relatively mild to moderate side effects, with leuko-
penia and alopecia representing the most common
toxicities. As compared with previous studies using
doxorubicin-containing combination regimens in
advanced STS,
21,32 the frequency of treatment-
related grade 3 and 4 toxicities was generally lower in
the present study.This might be due to the fact that,
in our study, the dose of doxorubicin of 50 mg/m
2/
cycle was lower, as compared with 60 mg/m
2/cycle in
other similar combination regimens,
21 concomitant
administration of radiotherapy and doxorubicin-
containing chemotherapy (i.e. during cycles 3 and 4)
was avoided and G-CSF was used on an only manda-
tory basis.CT was discontinuedin two patients (6%)
after two cycles due to impairment of wound healing.
Figure 1.
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all of which were given in the assigned dose and in a
relative dose intensity of 93%, illustrate the feasibility
of the chosen regimen. Due to standard anti-emetic
medication with 5-HT3-antagonists combined with
metoclopramide, no episodes of emesis grades III or
IV occurred. Furthermore, none of the patients
developed neutropenic sepsis.Most patients received
IFADIC on an outpatient basis,thus further stressing
the feasibility of the presently described IFADIC
regimen.
Despite extensive data on response to CT of
patients with metastatic STS,
33 only 13 prospective
randomized studies have been performed to combat
micrometastases by adjuvant CT following adequate
local surgical treatment of STS. Six studies included
single-agent doxorubicin in the treatment
protocol,
10,11,34± 36 whereas ® ve employed combina-
tion chemotherapy.
12± 16,37 One study was limited to
uterinesarcomas.
38A signi® cant differenceupon RFS
or OS was reported in only three studies,
10± 13whereas
® ve studies using single-agent doxorubicin in the
chemotherapyarm did notshow any signi® cantdiffer-
ence in either RFS or OS.
34± 38 However, a recently
published meta-analysis of 1568 patients
17 provided
evidence that adjuvant doxorubicin-based CT
signi® cantly improved local, distant and overall
recurrence-freesurvival. In addition,a trend towards
improved overall survival was postulated.
The present regimen of augmented adjuvant poly-
chemotherapy was chosen due to recent insights that
have shown that polychemotherapy including ifosfa-
mide and doxorubicin (the most active agents in adult
STS
19) exerts higher activity,as compared with mono-
therapy,
32 and a dose-response relationship for both
drugs in advanced or metastatic STS derived from
several trials.
39± 41 Finally, dose escalation by the addi-
tion of other agents extended the multidrug pro® le at
lower dose levels.
42 As only few data exist about the
efficacy of augmented CT for the adjuvant treatment
of STS,and following the already presentedconsidera-
tions, we have decided to administer the conventional
IFADIC regimen augmented in time by an abbrevia-
tion of inter-treatment-intervals by G-CSF support.
43
The results of our study indicated,however, that adju-
vant RT plus CT led to similar results in RFS, TLF
and TDF, as compared with adjuvant RT only and,
therefore,thatpatientswith STSful® llingthe employed
inclusion criteria derived no bene® t from CT
Table 4. Responses to treatment in patients with grade 3 soft tissue sarcoma (STS)
Reponse rates RT and CT (n=25) RT (n=16)
No evidence of tumor recurrence (%) 19 (76%) 7 (44%)
Overall relapses (%) 6 (24%) 9 (56%)
Local failures (%) 2 (8%)
1 5 (31%)
2
Distant failures (%) 5 (20%)
1 8 (50%)
2
Extent of tumor
‡ 10 cm 12 (48%) 7 (44%)
<10 cm 13 (52%) 9 (56%)
1Including one patient with local relapse and lung metastases.
2Including four patients with local relapse and lung metastases.
CT, Chemotherapy; RT, radiotherapy.
Figure 2.
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tive subgroup analysis of patients with grade 3 STS
revealed an advantage for the application of CT versus
RTaloneand showedevidenceof asigni® cantimprove-
ment of both RFS and TDF.Tumor relapse occurred
in 56% of patients with grade 3 STS from the control
arm, as compared with 24% of patients with identical
characteristics included in the chemotherapy arm
(p<0.05).Within this context,50% of patientsfromthe
control arm developed lung metastases, as compared
with 20% of patients from the chemotherapy arm
(p=0.04).However,this retrospectivesubgroupanalysis
hastobeinterpretedwith cautionduetoseveralreasons.
First,patientstrati® cationwas notcarriedoutfor tumor
grade duringthe randomizationprocess resultingin an
imbalance concerning treatment of STS patients with
both,grade 2 (12 patients in the control arm versus six
in the chemotherapy arm) and grade 3 (25 patients in
the chemotherapy arm versus 16 in the control arm)
malignancy. Second, the inclusion of more patients
with poorerprognosisintothechemotherapyarmcould
explain the trend towards improved RFS, TLF and
TDF observed in this group.Although only a relatively
small numberof patients with STS was includedin the
present study, its results are consistent with a meta-
analysis favoring adjuvant chemotherapy including
anthracycline
17 and, although not equally con® dent,
corroborate results of a study performedby Frustaci et
al.
13 who demonstrated improved RFS and OS in
patients with high-grade STS treated with adjuvant
chemotherapy.Adequatetumorstagingin STSpatients
should includechest CT scan. Inclusion criteria of the
presentstudy,initiatedin1992,consistedof chestX-ray
only due to the scheduledmulticentercharacter of this
trial. However, CT scan of the chest was performed in
95% of the patients, as they were included from
academic centers or central community hospitals.
Currently, all of the remaining 5% of patients are in
CR. Thus, a lack of initial staging cannot be held
responsible for the current results on relapse.
Furthermore, the low local recurrence rate of 6% in
the chemotherapy arm may be contributed to the
intensi® ed IFADIC regimen. However, this assump-
tion would have to be corroboratedwithin the frame of
arandomizedtrialincludinga largernumberof patients.
In contrast,the surprisinglyrelatively high local relapse
rate (21%) in patients receiving RT only probably
precludes hyperfractionated accelerated radiotherapy
as exclusive adjuvant treatment of high-risk STS
patients in future trials.
We thus conclude that the safety pro® le of intensi-
® ed IFADIC added to radiotherapy was manageable
and tolerable.Patients randomizedto receive intensi-
® ed IFADIC plus radiotherapy did not experience a
signi® cant bene® t concerning OS, RFS, TLF and
TDF,as compared with radiotherapy only.A potential
bene® t resulting from the administration of adjuvant
chemotherapy consisting of intensi® ed IFADIC for
patients with grade 3 STS needs to be further
validated within the frame of a prospective rand-
omized trial.
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